text:
Expected length of hospital stayDay Case
Private Knee - Arthroscopic Meniscectomy treatment prices.
|In London
|Outside London
|Under 16's
At HCA Healthcare UK we recognise the importance of giving our patients peace of mind and that is why our guaranteed fixed prices are fully inclusive with no hidden extras.
Please contact our dedicated team who will be happy to help you.
All treatments are subject to an eligibility criteria and terms and conditions.
HCA Healthcare UK hospitals offering Hip & Knee treatments
See below for the HCA hospitals that offer private Knee - Arthroscopic Meniscectomy treatment.
Consultants offering Hip & Knee treatments
Some of the country's top consultants choose to practice in our World-Class Private Hospitals and private units. See below for the consultants available for this procedure.
Private Hip & Knee treatments at HCA Healthcare UK.
HCA Fixed Price Self Pay makes it easy for you from the first telephone call.
0333 0110 500Contact Us
Would you like us to call you back at a more convenient time?
Leave your details and one of our team will be in contact.Call me back
Copyright © 2016 EIDO Healthcare Limited. The operation and treatment information on this website is produced by EIDO Healthcare Ltd and used under licence by HCA Healthcare Ltd.
The intellectual property rights to the information belong exclusively to EIDO Healthcare Limited. You may not copy, print out, download or otherwise reproduce any of the information other than for your personal, non-commercial use. The information should not replace any advice that your relevant health professional would give you.
No clinical treatment or procedure is risk-free nor can the results be guaranteed. Please refer to the EIDO Healthcare patient leaflet link above, for information about the associated common complications.
Find out about our external links policy.
Copyright © 2015 - 2019 - HCA Healthcare UK Self Pay Treatment is part of the HCA Healthcare Group.


text:
Reviewed by Kylie J. (age 12)
Zillah and Me illustration will appear here.
I thought that this book was an awesome book. I liked this book because it was fun-filled and it shows a great bond between two friends. My favorite part was when Zillah ran away and no one could find her not even the police. Katie knew where she was and she went to go get her. This story reminded me of the time I first met my best friend Christina and we didn?t like each other that much at first and then we became best friends.
I recommend this book to 4th- 7th grade girls because the girls in these grades may be going through the same thing right now and might be able to relate to this book. I think that girls who like friendship and fun books should like to read this. I think that the girls relationship might interest the girls because they hate each other at first and then they are best friends.

subset: commoncrawl


text:
All photos: Chris Wellhausen
Slopestyle course walk through from the Sochi Winter Olympics
Slopestyle kicks off the Olympic snowboard events at Rosa Khutor Extreme Park on Thursday when men and women drop in for the first qualifying round. Don't expect riders to hold anything back just because it's qualies—the top six men and women automatically advance to finals while the rest will have to battle in semifinals for the remaining six spots. With a two-run format that's a lot of incentive to put down a hammer run right out of the gate and secure a spot in the medal round. The riders know that, too—a bunch have already been spotted throwing triple corks in practice.
Earlier in the week the course design created some controversy after Torstein Horgmo broke his collarbone and riders like Seb Toutant and Roope Tonteri said they thought the course wasn't that safe. Shaun White echoed those comments when he dropped out of the competition late Wednesday afternoon saying, "With the practice runs I have taken, even after course modifications and watching fellow athletes get hurt, the potential risk of injury is a bit too much for me to gamble my other Olympics goals on."
Others like Sage Kotsenburg feel that things weren't that out of the ordinary. "We ride and after the first day the riders give feedback on the course," he said. "Then they [the course builders] work on it."
And today Chas Guldemond backed the course in a Facebook post when he wrote, "The jumps are sick and the flow is really good. Don't believe the media hype."
US Olympic team press officer Nick Alexakos also provided some context on what's happening behind-the-scenes, saying that while the jumps were poppy on the first day there have been open lines of communication at the riders meetings and changes have been made as they normally would at any event such as the X Games or Grand Prix.
There's also the theory that course designers made the setup bigger than usual because they were worried about warm weather that could shrink the features through melting. Which makes sense, because it's always easier to cut something back than to build it up once the basic structure has been set.
While there continue to be mixed feelings about the setup this much is sure: even with the tweaks the jumps are still huge. The action gets underway at 10 a.m. Thursday (Moscow Time Zone, 10 p.m. Wednesday, Pacific Time).


text:
CINCINNATI--(BUSINESS WIRE)--Dec. 13, 2012--
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has
successfully completed beta trials for two new illumigene molecular
amplification tests. These assays are designed to
specifically detect the DNA of Chlamydia trachomatis and Neisseria
gonorrhoeae, respectively, from both swab and urine samples.
For the first time, these two new assays will also incorporate Meridian
Bioscience's new nucleic acid preparation device which further
simplifies the illumigene test procedure. This novel
sample preparation device does not require excessive sample manipulation
steps, such as centrifugations or washing, and takes only five minutes
to process a clinical specimen. In the beta trial, performance of the
new illumigene assays was assessed against two
market-leading molecular platforms on a statistically significant cohort
of symptomatic patients. The trials were successful and satisfied
the design criteria for both assays. Total test time, from specimen to
results, for these new illumigene molecular tests was
approximately one hour on the illumipro-10™ Integrated
Incubator/Reader. It is expected that the clinical trials for regulatory
submission will begin later in the second quarter and should be
completed later in the third quarter.
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
infections are two of the most common sexually transmitted infections
worldwide. The WHO (World Health Organization) estimates that 92 million
new cases of Chlamydia trachomatis and 62 million new cases of Neisseria
gonorrhoeae occur every year. It is estimated that 4 million
Americans are infected each year by Chlamydia trachomatis and 1
million infected by Neisseria gonorrhoeae. CDC reported
1.2 million cases of Chlamydia in 2009 in the US, yet data
indicate that more than half of sexually active individuals are
Jack Kraeutler, Chief Executive Officer stated, "Since its market
introduction two years ago, the illumigene system has
enabled more than 950 acute care laboratories to adopt molecular
amplification testing without capital outlays and costly service
contracts. Since the launch of illumigene C. difficile,
our menu has rapidly expanded to include: a specific claim for testing
pediatric patients for C. difficile; illumigene
Group B Strep for prenatal testing; and, illumigene Group
A Strep which is useful either as a primary test or as a confirmatory
test in place of a two-day culture. In addition, the illumigene
Mycoplasma pneumonia test has been submitted to the FDA, and we
expect to submit our illumigene Pertussis assay to the
Agency later in the second fiscal quarter. The illumigene
system provides our lab customers with an essential capability for
improving the diagnosis of infectious diseases thereby helping to lower
the overall costs of healthcare delivery."
Meridian's continued growth depends, in part, on its ability to
introduce into the marketplace enhancements of existing products or new
products that incorporate technological advances, meet customer
requirements and respond to products developed by Meridian's
competition. While Meridian has introduced a number of internally
developed products, there can be no assurance that it will be successful
in the future in introducing such products on a timely basis. Meridian
relies on proprietary, patented and licensed technologies, and the
Company's ability to protect its intellectual property rights, as well
as the potential for intellectual property litigation, would impact its
results. Ongoing consolidations of reference laboratories and formation
of multi-hospital alliances may cause adverse changes to pricing and
distribution. Recessionary pressures on the economy and the markets in
which our customers operate, as well as adverse trends in buying
patterns from customers can change expected results. Costs and
difficulties in complying with laws and regulations, including those
administered by the United States Food and Drug Administration, can
result in unanticipated expenses and delays and interruptions to the
sale of new and existing products. The international scope of Meridian's
operations, including changes in the relative strength or weakness of
the U.S. dollar and general economic conditions in foreign countries,
can impact results and make them difficult to predict. One of Meridian's
growth strategies is the acquisition of companies and product lines.
There can be no assurance that additional acquisitions will be
consummated or that, if consummated, will be successful and the acquired
businesses will be successfully integrated into Meridian's operations.
There may be risks that acquisitions may disrupt operations and may pose
potential difficulties in employee retention and there may be additional
risks with respect to Meridian's ability to recognize the benefits of
acquisitions, including potential synergies and cost savings or the
failure of acquisitions to achieve their plans and objectives. The
Company cannot predict the possible impact of recently-enacted United
States healthcare legislation and any similar initiatives in other
countries on its results of operations. In addition to the factors
described in this paragraph, Part I, Item 1A Risk Factors of our Form
10-K contains a list and description of uncertainties, risks and other
matters that may affect the Company.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian's
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company's shares are traded through
NASDAQ's Global Select Market, symbol VIVO. Meridian's website address
is www.meridianbioscience.com.
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.John A. Kraeutler, Chief Executive
Officer, 513-271-3700


text:
Over the past year there has been much speculation that AMD and ARM would enter some sort of an IP licensing deal. Many expected to hear some big announcement like AMD licensing ARM's CPU cores or ARM licensing AMD's Radeon IP, but that didn't exactly happen. Yesterday at the AMD Fusion Developer Summit AMD announced the HSA foundation. The HSA Foundation partners AMD, ARM Imagination, MediaTek and Texas Instruments to come up with an open standard, you can find the full story on that here. Today though, AMD is extending the partnership with ARM to further reaches and has signed a licensing agreement with the company! AMD just announced that they are going to start implementing new
security measures into their future APU's (Accelerated Processing
Units) by using an ARM Cortex-A5 processor with TrustZone Technology. This means that AMD is licensing ARM cores and actually integrating them into their x86 based APUs as a platform security processor. AMD told us the company's "commitment to x86 hasn't changed," and that x86 is still here to stay.
AMD has been working on this for some time and is going to start introducing this technology select APU's in 2013. The first devices to see this technology should be fanless class (tablets and other small mobile devices). By the end of 2014 it will be implemented across AMD's entire product stack.
By utilizing a system-on-a-chip (SoC) design, AMD will begin
incorporating an ARM Cortex-A5 CPU into the APU. The ARM Cortex-A5 CPU
has been around for some time and features TrustZone technology which monitors and helps to protect the
system from malicious access to data and operations at a hardware level.
Adding the ARM Cortex-A5 cores and memory should be tough for AMD to do and it will not impact the manufacturing process. AMD informed it that it takes up a very little die space and will site off to the right side of the northbridge area. This allows it to power up first on the SoC and since the A5 processor has existing ecosystem with certified kernels it should easy to program for.
Shown above is the quad core version of the Cortex-A5. AMD did not mention how many cores will be included on for the platform security processor, but if we had to guess it would be less than four. By the time AMD releases processors with ARM IP on the we believe AMD will be manufacturing on the 28nm process, so adding just one or two cores shouldn't take up much space at all. After some quick math on our end we would guess the area to be smaller than 20mm^2.
The fact that AMD will be implementing a Cortex-A5 processor into AMD APUs might come as a shock to some, but remember that AMD is moving to a heterogeneous computing business model. Using an ARM Cortex-A5 CPU that features TrustZone technology to monitor and help protect against malicious access to sensitive data and operations at the hardware level looks like a good move for the future and will likely open the door to emerging technologies like NFC. The future looks good!
Comments are closed.


text:
"The most important function of education at any level is to develop the personality of the individual and the significance of his life to himself and to others." Grayson Kirk
To make education accessible to everyone who is willing to work for it is especially significant. That's what scholarship giving is all about; making education accessible.
Davenport University provides a variety of scholarships to our students through The Davenport Fund and the Davenport University Foundation. The scholarship awards distributed every year come directly from current gifts or investment earnings on past gifts to Davenport. Your support is vital to the growth of our scholarship program and to impacting lives that impact your communities.
Annual Scholarships
You can create an annual scholarship to be awarded each year. With a regular, annual gift you can establish a named scholarship and select the criteria you value. The scholarship will be awarded to a deserving student in your name or the name of someone you choose to honor.
Annual Scholarships at Davenport require a minimum annual commitment of $2,000 which can be made in a single contribution or spread out over the July to June fiscal year.
Endowed Scholarships
Contributions to an endowment fund are never spent. The interest earnings from these funds are used to make scholarship awards. Therefore, an Endowed Scholarship Fund remains in place in perpetuity. The dollars are invested and only a percentage of the income is used for student scholarships, preserving the fund for future spending needs.
Endowed Scholarships at Davenport require a minimum commitment of $25,000, which can be made in a single contribution or as an annual gift over several years. Donors are encouraged to add to their scholarship(s) even after the minimum of $25,000 has been reached. By increasing the balance, an increased award or number of scholarship awards can be given to students.
An Endowed Honorary or Memorial Scholarship can be established in another person's name which is a wonderful way to honor another person. The scholarship will help students for years to come while keeping alive an enduring memory of the person for whom the fund was named.


text:
I Musici/GazzeloniVivaldi Flute Cto.usedI Musici/Gazzeloni Vivaldi Flute Cto. Philips Import pressing 6570 186.Still in shrink. Recording produced by the great Volker Straus.The majority of Straus' career was spent with the Philips labe...9.00
Sorry, this listing has ended.
You may like one of these similar items:
I Musici/Gazzeloni - Vivaldi Flute Cto. Philips Import pressing 6570 [Expired]
no longer for sale
I Musici/Gazzeloni Vivaldi Flute Cto. Philips Import pressing 6570 186.Still in shrink. Recording produced by the great Volker Straus.The majority of Straus' career was spent with the Philips label in the Netherlands. In that association, he engineered significant recordings of such artists as Sir Colin Davis, Claudio Arrau, Henryk Szeryng, Josef Krips, Alfred Brendel, Dietrich Fischer-Dieskau, the Beaux Arts Trio, Ingrid Haebler, Sir Neville Marriner, and - above all - the conductor Bernard Haitink. His decades of production engineering for Bernard Haitink's recordings with the Concertgebouw Orchestra of Amsterdam form an imposing and diverse body of discs documenting the mainstream symphonic repertory. Straus' production of Haitink's Mahler symphony interpretations with the Berlin Philharmonic, Haitink's Brahms cycle with the Boston Symphony, and Haitink's Bruckner performances with the Vienna Philharmonic are notable for their engineering as well as their musical excellence.Have a nice big batch of Classical type music that I recently acquired from an audiophile.All discs in this collection have been closely inspected and have "no scratches" not even little ones!Will combine shipping.Buy multiple copies and I will ship for discounted rates to Cont'l. US only or Worldwide. PayPal for free.Typical Media rates are $6 for 1 LP and Priority rates are $8 for 1 LP. To all my International friends,please shoot me a list of LP's you want and I will weigh/get actual shipping charges for you. Thanks for looking. Please click on my >>(more from this seller)
tedmc member since November 2009
|Last 12 months
Items from this seller
- Stevie Wonder "Innervisions" (Kendun) 25% Easter Sale
Current Price: $22.00
- Blood,Sweat&Tears - Blood,Sweat&Tears Columbia 360 orig...
Current Price: $25.00
- Hampton Hawes Quartet - "All Night Session 2" Contempor...
Current Price: $17.00
more from this seller →


text:
Free Entry
Get a first-hand taste of Logan's cultural diversity at one of the city's hidden attractions, the Global Food Market. Shop amongst locals and pick up a range of seasonal produce you'd only expect to find overseas including; dragonfruit, jack fruit, custard apples, lychees, rambutan, mangosteen and much more.
While you're there, treat yourself to hot breakfast from a melting hot pot of global cuisines including South-East Asian, Indian, African, Pacific Islands, and tastes from the Middle East. The Global Food Village is on every Sunday, its admission is free and a truly wonderful culinary experience!
|Opening Hours
|All year
|6am - 12pm


text:
Mohammed bin Sulayem, the U.A.E. F1 representative was involved in a high speed crash while attempting to pilot last year's Renault R28 during the Renault 'Roadshow' at the Dubai Autodrome. Man, that's gotta hurt.
The FIA official driving the R28 was none other than Mohammed bin Sulayem, the U.A.E. automobile club president and FIA Vice President. According to early reports, the car swung heavily to the right under heavy acceleration on the main straight of the Dubai Autodrome, causing it to crash into a concrete barrier. Sulayem was subsequently sent to the on-track medical center and according to a Renault spokesman, he was uninjured and the car will be repaired to continue this weeks 'Roadshow.' [via F1-live]


text:
Bushies in Romneyworld
Mitt Romney's running as far as he can from George W. Bush.
In all three presidential debates, Romney's raced from the last Republican president's policies — claiming he's got new ideas for foreign policy, the deficit and energy.
Story Continued Below
But for all of Romney's efforts to divorce himself from Bush, behind the scenes there's one critical way he's given the era a full embrace: its people.
( Also on POLITICO: Mitt's 'W' problem)
Romney's brought on a cadre of Bush officials to serve as his senior policy advisers, lead his presidential transition effort and help him raise millions to fuel his run — the pillars of his campaign and a potential administration.
"Really, no coach wants to send a team on the field with all rookies," said veteran Republican fundraiser and strategist Fred Malek, who believes it's important for Romney to distinguish himself from his predecessor. "And the best thing to have is a combination of people with great experience and a track record so long as the energy and new ideas that come from new people that have not yet come from deeply in the government. I think that's really what Romney is looking to do and how the team shapes up to me."
On foreign policy, where Romney clearly distinguished himself from Bush on Monday night, 17 of Romney's 24 special advisers and the vast majority of his issue co-chairs worked in the Bush administration. Some of them are big names, like former Homeland Security Secretary Michael Chertoff, former CIA Director Michael Hayden and State Department vet Paula Dobriansky.
His transition team, which would staff up a potential administration, is run by Bush alum Michael Leavitt, former Health and Human Services secretary; Josh Bolton, Bush's chief of staff; Robert Zoellick, former World Bank president; and Emil Henry, who worked in Bush's Treasury Department, have also been in on the planning.
When it comes to raising money, Bush stalwarts are on board, including political operative Karl Rove, who has delivered personal briefings and fundraising appeals for the main super PAC supporting Romney.
Bush-era stars like Secretary of State Condoleezza Rice and former Vice President Dick Cheney have headlined fundraisers and attended mega-donor strategy sessions.
For its part, the Romney campaign says that he makes his own political calculations.
"Mitt Romney has assembled a diverse group of highly respected policy thinkers," said Romney spokeswoman Andrea Saul in an email. "He fields their opinions, evaluates them and ultimately makes his own decisions on policy."
But, that hasn't stopped President Barack Obama from trying hard to link Romney as having old, misguided thinking from the Bush era. At the debate in Boca Raton, Fla., Obama closed the evening by saying that Romney "wants to take us back to those policies, a foreign policy that's wrong and reckless."
Democrats believe linking Romney with Bush can be effective on the campaign trail.
"There is still a holdover that George Bush unnecessarily got us into war and then prolonged it, and that foreign policy combined with a really weak domestic policy sort of created the hole that we're in," said Democratic strategist Hilary Rosen.
Further, Rosen said that branding Romney with Bush is effective because he has "projected an old-fashioned view of the Soviet Union, of women, of education, of energy, and I think that continuing to tie him to sort of what are icons of the past helps Obama on his being a leader for the future."


text:
WTHS, the student-run FM radio station at Hope College, won four national awards during the 73rd annual conference of the International Broadcasting System Inc. (IBS), held in New York City on Friday-Sunday, March 1-3.
WTHS won first place among all college and university radio stations in the country for "Best Show Promo," for the segment "Freeze Frame" by junior Will DeBoer of West Lafayette, Ind., who is the station's production director.
The station won finalist awards, placing in the top five, in two categories: "Best Event Promo," for the segment "A Thanksgiving Tradition on WTHS," also by DeBoer; and "Most Innovative Show," for "The Stick" (Thursday, Nov. 29), by juniors R. Forrest Dodson of Kalamazoo, who is the station's general manager, and Christopher Rodriguez of Kalamazoo, who is the station's co-music director. WTHS also won a finalist award as one of the top six stations in the "Best Website" category for wths.hope.edu
Founded in 1940, the IBS is a not-for-profit education corporation that serves not-for-profit education-affiliated high school radio and college radio stations and streaming/webcasters, and has more than 1,000 member stations. The annual IBS Conference features more than 150 speakers and more than 1,000 attendees from all over the world. The conference featured finalist and winner awards in more than three dozen categories.
WTHS, which began in the 1950s as a "carrier current" station and spent more than 25 years on AM, has broadcast at 89.9 FM since 1985. The station features alternative college music, also highlighting activities on campus, local news, sports and current events. Its studio is in the college's Martha Miller Center for Global Communication.


text:
Winter 2000
The United Nations estimates that 16,000 individuals worldwide were infected with HIV each day in 1998; by year's end, more than 33 million people were living with the virus. At least 95% of all people infected with HIV live in regions with limited resources such as sub-Saharan Africa, where recently developed antiretroviral treatments are neither affordable nor widely available.
And while highly active antiretroviral therapy (HAART) has provided therapeutic benefit to those who can obtain and tolerate it, HAART has not cured a single individual. Nor has its use since 1996 been proven to reduce the rate of HIV transmission, apart from perinatal (mother-to-infant) transmission reduced through the use of nevirapine (Viramune) monotherapy, AZT (Retrovir) monotherapy, and AZT/3TC (Epivir) combination therapy. According to the Centers for Disease Control and Prevention (CDC), approximately 40,000 new infections occur each year in the U.S. -- a figure that has held steady for the past decade.
Many experts feel that a sustained decrease in HIV transmission and containment of the AIDS epidemic can be achieved only with widespread use of a safe, effective vaccine (though safer sexual behaviors and the use of clean needles will continue to be important components of AIDS prevention since no vaccine is 100% effective). Yet while substantial scientific effort, the diligent work of advocates, and a considerable outlay in funds have gone into creating HAART, HIV vaccine technologies have not been pursued with the same intensity in the pharmaceutical or biotechnology industries.
For these reasons, and in light of the needs of increasing numbers of HIV positive people, the general emphasis for many years has been on treating those already infected with the virus and advocating prevention by education and behavior modification. This is now changing, due in part to a growing awareness of the benefits of a vaccine coupled with an increased commitment by the government, private organizations, and philanthropists. Yet even though interest in vaccines seems to be gaining momentum, the development of a comprehensively effective vaccine strategy must overcome significant scientific obstacles.
Persistent viral replication, a hallmark of HIV, results in billions of new virus particles (virions) per day. The virus itself is highly unstable: mutant (genetically different) varieties of HIV proliferate rapidly during infection, resulting in the constant generation of virus that can escape recognition -- and thus regulation -- by the immune system. These mutant viral strains overwhelm the immune system's efforts to combat HIV with cytotoxic T-lymphocytes (CTLs, or killer T-cells) and antibodies, and leads to immunodeficiency and disease in almost all cases, at least without HAART. Protein structures on the HIV envelope (outer layer) are encrusted with sugar molecules, which further enables the virus's ability to elude the immune system.
Researchers have tried to adapt standard immunization methods or develop new ones to cope with the unique difficulties associated with the virus. A wide variety of approaches has already been evaluated: between 1988 and 1998, the AIDS Vaccine Evaluation Group (AVEG) of the National Institute of Allergy and Infectious Diseases (NIAID) conducted 47 studies using 22 different concepts. Although 36 vaccine candidates are currently in clinical trials in the U.S., most are in very preliminary stages. Shepherding research from the early stages into phase III efficacy trials has proven to be the most significant challenge for researchers.
Due to safety and practical concerns, early research done on vaccine candidates continues to rely on in vitro (test tube) models of HIV. The virus behaves quite differently, however, in a laboratory setting compared with a living human body. Promising vaccine approaches based on in vitro data therefore often fail in studies further along in the research pipeline. In fact, few of the vaccine approaches tested so far in phase I human trials have induced antibodies able to sufficiently neutralize primary isolates of HIV (Tat toxoid vaccines are a notable exception; see below).
Using animal models to evaluate experimental therapies in vivo (in a live animal) before testing them in humans also poses problems. To date, no perfect animal model has been found for replicating the effects of HIV in humans. Early studies in rabbits and other rodents (such as the severe combined immune deficiency [SCID]-hu mouse model) yield important data regarding immune responses to investigational vaccines and their relative safety, but transposing such animal data directly to human models can be extremely risky, especially when vaccine doses and concentrations are as yet unestablished.The so-called great apes, such as chimpanzees, are also potentially ideal research subjects since they are the only species besides humans susceptible to infection by HIV-1.
Yet most chimpanzee studies have been disappointing; these monkeys display a very low level of viral replication when infected with primary isolates of HIV, which furthermore induce disease in chimpanzees only after many years (similar to the human AIDS incubation period). Asian macaques can display AIDS-like symptoms rapidly when infected with virulent strains of simian immunodeficiency virus (SIV, a relative of HIV) or chimeric SHIV, a hybrid virus composed of an SIV core surrounded by HIV envelope proteins. Research using macaques is ongoing. Until a universally accepted approach for testing vaccine strategies in nonhuman primates is specified, few vaccine candidates will be considered for large-scale phase III efficacy trials in humans.
Researchers are trying to determine the optimal coordination of both arms of the immune system and the cytokines, or signaling molecules, that orchestrate them. At first it was believed that an HIV vaccine should provide sterilizing immunity (complete protection from infection), implying a key role for neutralizing antibodies. Because sterilizing immunity does not appear to be either feasible or (as with measles and hepatitis B) perhaps even necessary to prevent disease, however, vigorous production of CTLs -- along with Th1 helper cells, which are a particular subset of CD4 cells that help the CTLs work properly -- may be crucial to clear the virus or at least keep the viral load extremely low for an extended period of time.
The need for a strong cell-mediated response has been documented by studies of exposed but uninfected persons. Examples include African sex workers, selected long-term nonprogressors (LTNPs, or persons who do not exhibit immune dysfunction despite being infected with HIV for many years), health-care workers exposed to HIV but uninfected after a needlestick injury, and uninfected infants born to HIV positive mothers. Assays that measure CTL responses must be improved for a better understanding of their role in immune protection.
A successful vaccine strategy must also provide long-term protection against all clades (strains or subtypes) of HIV, especially those subtypes prevalent in sub-Saharan Africa (clades A, C, and D) and Southeast Asia (clade E). Most current HIV vaccine candidates have been tested only against laboratory strains of clade B virus, the subtype prevalent in Western Europe, Australia, Japan, and the Americas. Provoking immune responses at mucosal sites is crucial, as the most common mode of HIV transmission worldwide is by exposure to the virus at vaginal, rectal, and other gastrointestinal sites (including transmission to infants through breast milk).
Seroconversion induced by a vaccine is not identical to an infection with HIV. Although vaccinated individuals can be identified using the Western blot confirmatory test, HIV vaccines can produce false-positive results on the initial HIV antibody screening test (ELISA) and cause unnecessary trauma to the vaccinee. Preventive vaccination strategies therefore should allow vaccinees to be distinguished from HIV-infected persons. At present, those who have been inoculated usually are given a letter or card designating them as experimental vaccine recipients.
Treatment vaccines may work synergistically with HAART to control viral replication. Fred Valentine, M.D., of New York University, and colleagues reported on a 43-subject, 32-week, double-blind clinical trial of Remune (inactivated HIV) at this past year's 12th World AIDS Conference in Geneva, Switzerland. Remune is a treatment vaccine also known as the HIV-1 Immunogen or the Salk HIV vaccine. Persons treated with HAART and then immunized with Remune displayed a strong lymphoproliferative (increased production of CD4 and CD8 cells) response to a specific HIV core antigen, p24. A similarly robust immune response to p24 antigen also is seen in LTNPs and persons whose HIV viral load has been suppressed with HAART during acute infection (see also "Conference Coverage," BETA, October 1998). It is hoped that once viral load has been suppressed by HAART, an immune-based therapy, or vaccine such as Remune, can control further HIV replication without HAART.
Results from recent trials have been mixed. On May 17, 1999, an independent Data and Safety Monitoring Board (DSMB) advised the Immune Response Corporation of Carlsbad, CA, to halt its 2,500-subject, placebo-controlled phase III trial of Remune because differences in clinical endpoints (outcomes such as progression to AIDS or death) were not observed between those who added the vaccine to their anti-HIV therapy and those who did not. HAART became the standard of care after the trial began; its use may have masked additional benefits rendered by the vaccine. Studies of 250 of the participants showed that those who took Remune displayed a greater reduction in their HIV viral loads and an increase in lymphoproliferative responses at 48 and 96 weeks. Clinical endpoints thus may have been misleading indicators of the long-term efficacy of combining HAART with Remune; to gather more pertinent data, phase II trials to analyze secondary endpoints (surrogate markers such as viral load and lymphocyte production) are currently being done in Argentina, Spain, and Thailand.
In addition, a pivotal phase III trial in North America, Europe, and Australia has recently been announced. This 48-week study will try to determine whether adding Remune to a specific HAART regimen (nelfinavir [Viracept] and AZT/3TC [Combivir]) delays the onset of virologic failure in treatment-naive individuals. Failure in this context means that viral load either does not decrease to below 50 copies/mL or rebounds to greater than 50 copies/mL. For more information, call 877-858-7783.
A much smaller, 40-subject Remune trial for HIV positive persons already taking HAART has also started enrolling at the University of Alabama at Birmingham. Participants will receive injections of Remune at weeks 0, 12, and 24, then stop their antiretroviral therapy at week 28 to determine if their viral loads remain suppressed (i.e., below 50 copies/mL) without HAART. For more information, call 205-975-9127.
In Europe, a phase II trial conducted by the European Multinational IMMUNO AIDS Vaccine Study Group showed that a therapeutic vaccine based on a recombinant, or genetically engineered, surface glycoprotein (rgp160) conferred no clinical benefits in trial volunteers. According to a report in the August 20, 1999 issue of AIDS, 96 treatment-naive volunteers with CD4 cell counts greater than 500 cells/mm3 and 112 treatment-experienced volunteers (51 of whom were on treatment with one or two nucleoside analog [NRTI] drugs) with CD4 cell counts ranging from 200-500 cells/mm3 participated in the trial. Frank D. Goebel, M.D., of the University of Munich, and colleagues administered monthly injections of either the rgp160 vaccine or placebo (an inactive substance) to the participants for six months. Booster immunizations (supplementary vaccine doses) or placebo were subsequently given after 15, 18, and 21 months.
At the two-year follow-up, Dr. Goebel's group found that the vaccine had no effect on the participants' viral RNA or proviral DNA levels despite the initiation of rgp-160-specific lymphoproliferative responses. Because the rgp160 vaccine had no effect on the natural history of HIV infection among trial subjects, the Study Group concluded that this particular vaccine is not highly efficacious and should no longer be pursued.
Immunologists are now exploring ways of combining DNA vaccines with adjuvants (immune stimulators) to elicit immune responses strong enough to protect the body from future infection and optimize the ratio of cellular to humoral responses. For example, incorporating genes for certain cytokines (such as interleukin 2 [IL-2] and IL-12) and chemokines (such as MIP-1 alpha) into DNA plasmids has been shown to boost CTL responses to HIV. (Chemokines are cytokines that attract and activate lymphocytes. For more information on chemokines and vaccines, see "Chemokines and HIV," BETA, March 1997.) DNA vaccine constructs can be further engineered to carry genes from different strains of HIV, potentially providing immunity against several clades at once. The ability to manipulate and customize DNA vaccine therapies is one of their most attractive features. DNA vaccines are believed to be unable to cause HIV infection -- an obvious safety concern with most candidate vaccines -- since they lack the genes necessary for viral replication. Moreover, DNA vaccines are easy to design and generate in large quantities, and therefore should be relatively inexpensive to produce and distribute throughout the world (see also "DNA and Other Technologies for HIV Vaccines," BETA, April 1998).
In July, Dr. Emilio Emini of Merck & Co., based in Whitehouse Station, NJ, confirmed reports that Merck was planning to begin human trials of two experimental vaccines, including a DNA-based approach aimed at eliciting significant amounts of CTLs. John Shriver, also of Merck, explained that their approach involves genetically altering HIV genes to "humanize" their sequences, (i.e., by changing some of the DNA codons -- specific nucleotide sequences -- to those found most commonly in humans). Merck's other vaccine will be a live vector-based approach of unknown composition that will probably serve as a booster dose for the DNA model. The trials should begin enrolling by the end of this year.
Researchers are investigating the potential of avian (bird) pox viruses, such as attenuated (weakened) canarypox, which have a limited ability to replicate in the body. It has not yet been determined if such vectors will provide a strong, reliable, and long-lasting CTL response. In July, Dr. Robert Belshe of the St. Louis University School of Medicine reported on a multicenter, phase II trial of Pasteur Mérieux Connaught's canarypox vector ALVAC vCP-205 combined with Chiron Vaccine's recombinant glycoprotein 120 (known as SF-2 rgp120). Over 400 participants received either the vector plus rgp120, the vector plus saline, or placebo plus saline at trial start and at intervals of one, three, and six months.
Not surprisingly, the neutralizing antibody response was greatest in those who received the vector plus rgp120; however, a CTL response was demonstrated in only 30% of vaccinated subjects at any given time. Such a low CTL response level has raised questions about the utility of this canarypox. Other vectors being evaluated include adenovirus, modified vaccinia Ankara (MVA), Venezuelan equine encephalitis virus (VEE), other alpha viruses (including Semliki Forest virus), and enteric (intestinal) bacteria such as salmonella.
Most subunit vaccines are monovalent, meaning they have only one molecule against which an immune response can be directed. Antibodies generated by monovalent subunit vaccines have not been able to neutralize primary isolates of HIV efficiently, nor can they neutralize more than a limited number of strains. Development of a bivalent vaccine -- for instance, using rgp120 from one strain of HIV and combining it with rgp120 from another -- has resulted in an antibody response of much greater breadth.
The only phase III efficacy trials of a prophylactic HIV vaccine to date involve a bivalent rgp120 approach known as AIDSVAX, developed by Donald P. Francis, M.D., of VaxGen, Inc., based in Brisbane, CA. One study -- with 60 trial sites in North America and one in Amsterdam -- is enrolling 5,000 volunteers who will be randomized to receive vaccine (based on clade B viruses) or placebo in a 2:1 ratio and monitored for three years.
The other study -- using a bivalent vaccine based on clade E viruses -- is ongoing at 17 trial sites in Bangkok. Many people question the value of testing gp120 vaccines like AIDSVAX in phase III trials because they do not induce CTL production and, even with a bivalent structure, they may not produce antibodies capable of neutralizing adequate amounts of primary HIV isolates. Others feel encouraged that at least one prophylactic vaccine candidate has reached a relatively advanced stage of development despite its apparent drawbacks.
This unfavorable outcome was observed in a study conducted by researchers at the Dana-Farber Cancer Institute in Boston involving 16 adult macaques. As reported in the February 1999 issue of Nature Medicine, four monkeys in the trial had HIV in their blood, one displayed some immune dysfunction, and one died of AIDS; all had been inoculated with a weakened strain of SIV that lacked three different genetic elements (nef, vpr, and the Nef-responsive element, or NRE) involved in viral replication.
Recent news from Australia has dealt another blow to the prospect of using a live, attenuated HIV vaccine in humans. A report in the June 3, 1999 issue of the New England Journal of Medicine indicated that three Australians infected with a strain of HIV lacking a functioning nef gene were experiencing immune system damage, including detectable viral loads and declining CD4 cell counts. The three were among a group of nine people -- including a blood donor and eight people who received transfusions of his blood before 1985 -- infected with the same attenuated HIV strain. Known as the Sydney Blood Bank Cohort, the remaining six members of this group appeared to be LTNPs (three have died of causes unrelated to HIV infection). The fact that some of them are now showing signs of disease progression indicates that attenuated HIV may never be safe enough to use in a vaccine (see also "News Briefs," BETA, Summer 1999).
Studies done in 1991 with whole-killed SIV revealed that the protective immunity seen in macaques was due to antibodies directed against the cells in which the vaccine virus was cultivated and not the virus itself. This discouraging study derailed most whole-killed vaccine research. Immune Response Corporation, which developed Remune (made from a whole killed, gp120-depleted virus), is among the few companies still exploring this technology.
Researchers have noted that many structures displayed by this infection process would make excellent targets for neutralizing antibodies. The chemokine receptor site, which remains occult (hidden) until gp120 binds to the CD4 site, is one such target. Antibodies could also prevent cell fusion by binding to different parts of the transitional gp41 apparatus. Since these targets appear only fleetingly during viral infection, however, the means of utilizing them remained unknown. Jack Nunberg, Ph.D, and colleagues from the University of Montana, who published their findings in the January 15, 1999 issue of Science, may have solved this problem. Dr. Nunberg's team prepared a mixture of mouse cells displaying HIV Env proteins and human cells expressing both the CD4 and chemokine receptors. Formalin (a 40% solution of formaldehyde preservative) was added before the mouse and human cells fused together, thus freezing their activity -- and presumably capturing the Env proteins in a "fusion-competent" state.
To the surprise of many scientists, this idea worked. When the mixture (without formalin) was injected into mice, their antibodies not only could neutralize HIV, but they also were able to neutralize 23 of 24 different strains of HIV isolates taken from persons living in various regions of the world. This broad neutralization ability, which is essential for an HIV vaccine, had never been seen before. Dr. Nunberg's technique will no doubt serve as a model for future vaccine efforts; experiments in larger animals such as macaques are likely to ensue.
Initial, preliminary studies are quite promising. In a recent article published in the Proceedings of the National Academy of Sciences, Dr. David I. Cohen of Queens College in Flushing, NY, and colleagues suggest that the activity of Tat may explain why almost all vaccine candidates to date have failed. Dr. Cohen's team claims that every prophylactic vaccine strategy must take into account Tat's immediate assault on the immune system, because Tat will destroy immune responses brought on by any other part of the virus, such as envelope proteins.
Although Tat toxoid injections have not been able to prevent SIV infection in macaques, results of a phase IItrial of 30 HIV positive subjects (presented by Alessandro Gringeri, M.D., of the University of Milan, Italy) indicated that an experimental Tat vaccine was safe and able to induce a humoral immune response in all participants after seven injections. A phase III protocol based on this study has been developed. In the September 17, 1999 issue of AIDS Treatment News, Robert Gallo, M.D., Director of the Institute of Human Virology, announced that combining Tat toxoid with a vaccine against interferon-alpha, a type of cytokine, stabilized CD4 cell counts in persons taking no other anti-HIV therapy. (An overproduction of interferon-alpha, which is commonly seen in HIV positive people, inhibits the growth of lymphocytes.)
To elucidate the benefits of this combination, large-scale trials will need to be done. Researchers believe that injections of Tat toxoid will be used primarily as a therapeutic vaccine (in concert with other anti-HIV therapies) and as a possible component of a prophylactic vaccine. Because it is inexpensive, easy to administer, and far less complicated than HAART regimens, a Tat vaccine may one day play an important role in combating AIDS throughout the developing world.
Is there a conflict of interest when vaccine trial researchers offer prevention services to trial subjects yet depend on witnessing HIV infections to determine if the vaccine works? Can there be an international standard for informed consent? Is it fair to use people from resource-poor nations in vaccine trials if a successful vaccine most likely will be used primarily for people in developed countries? And once a vaccine is ultimately developed, will it be affordable and accessible for all people?
Such questions do not have easy answers. According to the September 11, 1999 issue of the Lancet, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has revised its universal ethical guidelines concerning HIV trials, despite the fact that consensus on many key issues could not be reached.
Private organizations are stepping in to fund research and foster an environment for vaccine development by expanding public/private collaboration and investment. The American Foundation for AIDS Research (amfAR) has awarded seed grant money to a number of vaccine researchers, including Dr. Jack Nunberg, whose amfAR funds enabled him to complete his breakthrough work on fusion competency. The International AIDS Vaccine Initiative (IAVI), established in 1996, works on a variety of fronts to speed development and ensure distribution of preventive HIV vaccines. In all of its projects, IAVI emphasizes the need for a global vaccine effort; for example, it encourages pharmaceutical and biotechnology companies to conduct multiple clinical trials in different populations, especially in developing nations, to test vaccine efficacy against all HIV clades.
Private donations to IAVI are escalating, most notably from the Bill and Melinda Gates Foundation (Bill Gates is cofounder of the Microsoft Corporation), which donated $25 million as a five-year grant to IAVI this year. And a group of volunteer advocates located across the U.S., known as the AIDS Vaccine Advocacy Coalition (AVAC), has been goading the pharmaceutical and biotechnology industries, the government, and others to focus more energy and resources on vaccine development.
Perhaps due to input from organizations like AVAC and IAVI, U.S. government support is slowly on the rise. In an address to the United Nations General Assembly on September 21, 1999, President Clinton announced his intention to host a conference on vaccine development to spur investment and interest in vaccines against AIDS and other diseases.
This announcement came on the heels of Clinton's June dedication of the Dale and Betty Bumpers Vaccine Research Center at the National Institutes of Health (NIH), whose mandate is to develop an HIV vaccine under the guidance of newly appointed director Gary Nabel, M.D., Ph.D. Anthony Fauci, M.D., director of NIAID, notes that 11% of the NIH's current $1.8 billion (i.e., $198 million) allocated for AIDS research is devoted to vaccine research.
And late last year, President Clinton pledged to increase the NIH's AIDS vaccine research spending by 33%, to $200 million. In March, Representative Nancy Pelosi (D-CA) introduced the Lifesaving Vaccine Technology Act (H.R. 1274), which would provide a 30% tax credit for research and development expenditures on vaccines for tuberculosis, malaria, and HIV/AIDS. On October 12, Senator John Kerry (D-MA) introduced an identical bill (S. 1718) in the Senate. (As this issue of BETA went to press, Congress had not yet voted on either measure.)
A certain degree of support has been shown even on the state level. In September, the state of California awarded a six-year, $7 million grant to the University of California at San Francisco, which will use the funds to launch a new AIDS research center; part of its program will focus on HIV vaccines.
A movement is also afoot to create an international vaccine purchase fund. Such a fund would stimulate vaccine research and development by guaranteeing that any successful vaccine would be purchased in sufficient quantities at a certain price to provide a favorable return for the developer. Pharmaceutical companies therefore would enjoy the freedom and flexibility to pursue their own lines of inquiry without relying on government funding or directives.
Nicholas Cheonis is Editorial Assistant of BETA.
Back to the SFAF BETA Winter 2000 contents page.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.


text:
Piazza Dog Bed In Melody
[Comfort] Squared !
Inspired by the Italian Piazza (pi-az-za), an open public square and center of public life in many of Italy's towns. Dogs are sure to be drawn to the tufted square fibre topped foam center cushion and will be pampered with the plush overstuffed outer bolsters. The Piazza captures the sleek, space saving modern design of traditional flat cushions with the added security and comfort of removable bolsters. The cover features a convenient carry handle and is completely removable for washing and drying.
Choose between:
Medium - 28" x 28" x 7" for dogs up to 50 lbs
Large - 34" x 34" x 7" for dogs up to 80 lbs


text:
FFA chapters earn $12,900 in Pfizer Animal Health marketing contest
Nine chapters receive awards for participating in nationwide marketing contest
MADISON, N.J. — Sept. 27, 2012 — FFA chapters across the country partnered with local veterinarians and Pfizer Animal Health representatives to promote responsible, economic and proper use of Pfizer Animal Health products — and nine chapters earned $12,900 in the process.
"Pfizer Animal Health and our partners are longtime supporters of the values, education and experience FFA offers," says Julian Garcia, group marketing director with Pfizer Animal Health. "This contest allowed individual chapters to showcase their industry knowledge and practical experience. Not only did these chapters earn funds to help support their activities, but the students made deeper connections to the industry that can help them as they become our future leaders."
The first-place chapter, Paris FFA in Paris, Mo., received $2,500 and a trip to Pfizer Animal Health's headquarters in Madison, N.J., for the chapter advisor and four students. While visiting Pfizer Animal Health, the chapter representatives will present the winning plan to a group of the company's marketing and sales colleagues. The chapter plans to use the funds to help support daily FFA operations and to provide its members the opportunity to attend conferences at the local, state, and national levels.
"Watching my students work and dedicate their lives to FFA and help promote the agriculture industry is what gives me faith that the future of agriculture is so bright," says Josh Bondy, Paris FFA, chapter advisor. "Members of Paris FFA worked to develop a marketing plan for Pfizer Animal Health products, and they implemented that plan with the help of our local veterinarian, Dr. Mac Wilt (Paris Vet Clinic). The FFA motto states: 'Doing to Learn,' so thank you Pfizer Animal Health, Dr. Wilt and the Paris community for providing us this opportunity. Our students are now better prepared for college and to enter the agriculture workforce."
FFA chapters participating in the marketing contest worked with a local veterinarian or animal health supplier on an educational program, producer meeting, open house or other initiative to promote the effective, economic and proper use of cattle and/or equine animal health products. Then, each chapter submitted a plan summary including objectives, descriptions of the process and outcome and submitted photos and metrics determining their success.
For the Paris FFA Chapter, the contest allowed the students an opportunity to work with their local veterinarian and provide a platform to educate and interact with local livestock producers.
"On our farm, we frequently use Pfizer Animal Health products; these products have helped to ensure the health of our animals and maintain a high level of productivity. By having this opportunity to develop a marketing plan for these products and interact with customers, I feel better prepared to enter veterinary studies in college." says Britton Francis, senior Paris FFA member.
The chapter participated in two events to promote Pfizer Animal Health products: Monroe County Ag Night and Steer Weigh-in Day. The FFA members were able to get everything needed to put these events together by donation. Their local veterinarian, Dr. Wilt, was at both events to talk to potential customers about Pfizer Animal Health products. Overall, the chapter was able to reach 350 prospective customers between the two events. In addition to the FFA members providing information on animal health, local agricultural leaders had a chance to see the future of agriculture in action.
"The Monroe County Ag Night was a huge success; it was very motivating to see everyone in the county with the same mind set, improving agriculture. Thank you to the Paris FFA and Paris Vet Clinic for setting up and educating us for the evening," says Megan Morgan, local row crop and cattle producer.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc., is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. For more than 60 years, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them. To learn more, visit www.pfizeranimalhealth.com.
Full list of winners and partners:
First place ($2,500 award and a trip to Pfizer Animal Health headquarters for four students and the chapter advisor):
· Paris FFA in Paris, Mo. (Partners: Dr. Mac Wilt, Paris Vet Clinic)
· Advisors: Josh Bondy and Stephanie Eckler
Second place ($2,000 award):
- Valentine FFA in Valentine, Neb. (Partners: Dr. Rogers & Dr. Larson)
- Advisor: Gregory Nollette
Third place ($1,500 award):
- Newell-Fonda FFA in Newell, Iowa (Buena Vista Veterinary Clinic)
- Advisor: Crystal Walters
Honorable mentions ($1,000 award):
- Cascade FFA in Cascade, Iowa (Partner: Rolling Hills Veterinary Clinic)
- Central Columbia FFA Chapter in Bloomsburg, Pa. (Partner: Bloomsburg Vet Hospital)
- Hartsburg-Emden FFA in Hartsburg, Ill. (Partner: Timbercrest Veterinary Service)
- Turlock-Pitman FFA Chapter in Turlock, Calif. (Partner: Paul Fernandes)
- R.G. Drage C.T.L. FFA Chapter in Massillon, Ohio (Partner: Mavare Animal Clinic, DVM Jodi Steward & DVM Randy Stern)
- Woodbridge FFA in Bridgeville, Del.
©2012 Pfizer Inc. All rights reserved. GCA11229


text: harold miller Paying for Quality, Not Quantity By Jacob Fenston • Oct 28, 2011 futurestrategies.org In the United States, we pay a lot more for our health care than other wealthy countries, but we are no healthier. Missourians actually pay even more per capita than the U.S. average, and are even less healthy. (Missouri is ranked 39th in the nation in overall health, and we are the 9th most obese state.) A big part of the problem is the way we pay for health care, according to Harold Miller, executive director of the Center for Healthcare Quality and Payment Reform.


text:
≡ Menu
About Richard Worzel
Photos to Download
What's a Futurist? (FAQs)
Contact & Booking
Futuresearch Blog
Blog Posts
Subscribe to Blog
Conference Handouts
Keynote & Workshop Topics
Futuresearch Mailing List
Future of Food
Why Traditional Farming Is Here to Stay
Richard Worzel
February 15, 2016
The Future of Food: Farming It, Processing It, Packaging It, Selling It, Eating It
Richard Worzel
January 23, 2013
Search Futuresearch.com
Conference Handouts
Recent Posts
What Should We Do About Wasting Food?
What's the Most Overlooked Driver of Climate Change?
From Crush to Crash: The Future of Video-On-Demand
Is Using the Internet on Exams Cheating?
Your Job, Not Your Car, Is Killing the Environment
Why Millennials Will Pwn The Future
Should Self-Driving Cars Be Banned?
The Conquest of Health Care in America
Bitcoin Is Dangerous – and Worthless
What's Happened to Inflation? And Why Does It Matter?
Richard Worzel on Twitter
Tweets by @futureworzel


text:
WrbCit is a windows contest logging software supporting the 40/80 Italian Contest by IK0WRB in Italian
Hits: 151 | Votes: 0 | Rating: 0.00
About WrbCitThe resource is currently listed in dxzone.com in a single category. The main category is Ham Radio Contest software that is about Contest program for ham radio contesting events, list of contest software. This link is listed in our web site directory since Saturday Sep 27 2014, and till today "WrbCit" has been followed for a total of 151 times. So far no one has rated yet, so be the first to rate this link !
You may find other interesting sites similar to this one, under the following categories:
- Software/Contesting - Contest program for ham radio contesting events, list of contest software
Rate this resourceno one has rated yet, so be the first to rate this link !
The scale is 1 - 10, with 1 being poor and 10 being excellent.
Webmaster, add a Remote rating
WrbCit - related linksWe thought you might also be interested in these additional web sites, selected from the same category:
Share WrbCitShare this link with your friends, publish within popular social networks or send it via email.
About Us
The DXZone is the largest human created and maintained library of web sites dedicated to Amateur Radio, currently lists 20.000+ links organized into 600+ categories. Real Hams review new sites every day since 1998, for potential inclusion in the Directory, and to evaluate the best place to list them.
Sign up to our Newsletter
Get our latest news and links in your email. Service provided by Google FeedBurner


text:
The East Hampton Village Board will attempt to stop John and Suzanne Cartier from building a second house on their property at 105 Main Street, even though the zoning board of appeals determined earlier this month that their plans conform to zoning requirements.
The village board voted on Friday to hire the law firm Lamb and Barnosky to commence legal actions to "preclude the proposed disturbance of the premises," which is covered by a scenic easement granted to the village in 1975.
Village code currently allows second residences for domestic employees or family members to be built on certain properties large enough to be subdivided, as long as both houses conform to zoning in every way should those properties be divided in two.
After being denied a building permit in 2010 to relocate and reconfigure their main house and build a second one elsewhere on their two-acre property, the Cartiers applied to the Z.B.A. earlier this year for variances. Following four months of review, the zoning board determined that the variances requested were not necessary because both houses as proposed would conform to zoning code requirements for large lots.
However, the village board believes that a scenic easement granted when the property was subdivided in 1975 "does not permit a second home to be built on it," said Larry Cantwell, the village administrator.
The village is responsible for enforcing the easement, and is hoping a judge will stop the Cartiers from moving ahead with their plans.
At the same time, the village is seeking to eliminate the section of the code allowing second houses on certain single lots. Generally, in a residential district, only one house is allowed per property. If the change, subject to a hearing on Dec. 21, is approved, property owners would no longer be able to build second houses on their property unless they first subdivide it. "One house, one lot, period," Mr. Cantwell said.


text:
No man is an island, but Larry Ellison comes close.
Last year, Ellison bought 98 percent of Lanai for more than $500 million. Despite a wispy beard and penchant for black outfits that make him look like a devil, he's mostly being hailed as a white knight by an island still struggling to find its post-pineapple identity.
Ellison wants to double down on the previous owners' bet that luxury tourism can be an economic driver on the 141-square-mile island.
Good for him, though I'm probably not the kind of visitor he is courting for his future luxury playground.
Ellison wants to upgrade the two existing Four Seasons resorts, build an upscale eco-bungalow "Club...


text:
Ferrari 2013 Yearbook
The Official Ferrari Magazine 2013 Yearbook covers all the information, news and events that shaped the season.
In keeping with tradition, the year ends with the publication of the legendary Ferrari Yearbook, which reviews the most important events of the Maranello-based racing brand. The 2013 edition is a special one, featuring a lot of previously unpublished information, including how the La Ferrari is built, step by step, and management meetings between the chairman Luca Cordero di Montezemolo and his team of staff and production technicians. The publication is packed with exclusive photographs.
- Glossy paper
- High definition photographs
- Text in English
- Composition: 100% Paper
We offer both Standard and Express shipping: choose the service that best meets your needs at checkout.
We provide an easy return service: just ship your items back to us with a shipping service of your choice within 30 days of delivery.


text:
BURBANK — A mask with a baseball still lodged in the face guard that was used by one-eyed umpire Max McLeary; Ron Santo's partially burned toupee; the costume head of the San Diego Chicken and a box of balls with the forged signature of Mother Teresa.
The items are only a small representation of the unique, interesting and often bizarre collection of memorabilia that is featured in the exhibition, "Not Exactly Cooperstown," that is currently on display at the Burbank Central Library. The collection will be featured in the library's entrance lobby until Sept. 29.
The exhibition is hosted by the Pasadena-based Baseball Reliquary, under the direction of executive director Terry Cannon. Cannon said his organization strives to stage displays that include memorabilia and baseball-related items that catch the attention of fans, even if they are a little off-beat like those featured in the "Not Exactly Cooperstown" collection.
"This is what we like to collect," Cannon said about the current display that is free to the public. "What's different about the Baseball Reliquary from other sports or baseball museums is that we look to collect what I like to refer to as curiosities or oddities; things that are kind of off the beaten path of collecting. But I like items like these because many of them are eye-catching and different."
Cannon said when the Baseball Reliquary puts on a collection, it isn't just a hodgepodge of items thrown together.
"Everything that we do collect, like these items, I like to make sure it's representative of an interesting story related to the game," he said. "The artifact then becomes a kind of way of illustrating a story."
Most of the items displayed in the "Not Exactly Cooperstown" display have separate signage cards that give information and background about the memorabilia piece.
Some of the other items in the collection include:
•A humanitarian award given to Ty Cobb, one of baseball's most caustic and continuous personalties.
•Pitcher Dock Ellis' hair curlers, which he wore during pregame workouts, and Joe Pepitone's 1960s Chic model blow dryer, as part of a salute to hair.
•Memorabilia from the House of David, a talented barnstorming religious team that was one of the first integrated squads.
•A psychedelic, peace-and-love jersey worn in 2010 by the Stockton Ports for a "Salute to the Beatles Night."
•Paintings depicting the most valuable baseball card in history, the Honus Wagner T-206 tobacco card, along with a selection of artist-designed and defaced baseball cards.
"One of the things about the Baseball Reliquary that I think is unique is that we span the gambit form the silly and irreverent to the scholarly," Cannon said. "And having the head from the suit of the famous San Diego Chicken really represents the fun side of baseball, which is all too lost nowadays on the game."
The Baseball Reliquary has been using the Burbank Central Library to stage its exhibitions for 10 years.
Library assistant Joan Cappocchi, who is in charge of programs and publicity for the facility, said the Baseball Reliquary's displays are always a hit with patrons.
"We always like working with the Baseball Reliquary because of their unique spin on baseball," she said. "There are some things that you just can't find anywhere. What they do bring attracts a lot of people to the library, people who might not normally come to the library."
Cannon pointed out that along with the exhibition, the Baseball Reliquary is working out the details for a program at the library, tentatively set for Sept 17. The program would include a panel discussion, a book signing and feature former baseball players.
Priding itself as a museum without walls, the nonprofit Baseball Reliquary travels across Southern California presenting exhibitions and programs in a variety of public settings.


text:
- User Name: letamoon
- Member Since: Saturday, May 8, 2004, 8:52 PM
- Donation Level: Total Leech (Donator)
- Name: Christina P
- Studio: Itsuki Hatakai Productions - Formerly Sephy-sama Productions
- Location: Edmonton, Alberta, Canada
- Homepage: https://www.youtube.com/ItsukiHatakai/
- Last Login: 2015-09-08 03:58:55
- Forum Info: Profile Posts (5)
- Worthy Banners: 1 worthy banners
- Usefulness: 37 with
3 opinions
[average 119.5 of 231572 opinions; standard deviation 432.3 ]
- Profile: Hello there!
About Me
Youtube name: Itsukihatakai
Age: 27
Favorite color: Pink
Editing tools of choice: Pinnacle Studio
I love going to anime conventions and also creating cosplay. I love to sew, draw, and voice act.
I've been watching amvs for most of my life. I started watching amvs on amv.org however way way back to about 2001. I'd sit there and wonder.."people must have real skill to make a music video using anime and music" I thought the combination was brilliant. I then started making my own in 2002, Starting it all off with my first ever amv that I wish I still had, Shooting star to Hand Maid May. Now here I am, continuing making amvs and growing and learning more as I go.


text:
World Bulletin/News Desk
Torrential rains were forcing residents and tourists to flee coastal areas along the Great Barrier Reef as the strongest cyclone in three years barrelled across the Coral Sea for the Australian mainland.
Tropical Cyclone Ita is forecast by meteorologists to cross the coast near Cooktown on Australia's far northeast coast between 1100 and 1400 GMT.
Residents refusing to be evacuated to shelters or higher ground by emergency crews and police are being warned to hide in their bathrooms until the worst of the storm passes.
"We all can get through this without anyone being injured or killed," Queensland's Premier Campbell Newman said. "I want people to know you are not alone. We are all being backed up by a very big team."
Wind gusts of up to 300 kmh (186 mph) and widespread flooding are forecast through the weekend.
"While the strongest winds are focussed near the centre, the warning area for tropical cyclones of this intensity is quite broad with destructive winds, heavy rainfall possibly leading to flash flooding, and coastal inundation due to storm surge all posing a threat," said Rob Webb, Queensland regional director at Australia's Bureau of Meteorology
The storm's projected course should put an area stretching for 400 km (250 miles) at the greatest risk, emergency officials said.
The storm's erratic path makes pinpointing precisely where it will make landfall difficult, according to meteorologists.
People are being warned not to venture outside if they find themselves in the calm centre, or eye, when the storm passes as very destructive winds from a different direction could resume at any time.
The storm was still classified as a tropical depression when it marched across the Solomon Islands late last week, killing at least 23 people near Honiara, the capital, according to the United Nations.
Sugar farmers in Queensland, who grow about 95 percent of the sweetener produced in Australia, are bracing for potential damage to up to 7 million tonnes of cane, industry groups said.
Australia, the world's third-largest exporter of raw sugar, has seen production devastated by cyclones in the past, driving up world sugar prices as buyers scramble for alternative sources of supply.
In 2011, Cyclone Yasi ripped through more southern parts of Queensland, destroying crops and causing over $3 billion in property damage and tourism business.
Before Cyclone Ita, sugar production in 2014/15 was forecast by the Australian Bureau of Agriculture and Resource Economics and Sciences to rise to 4.4 million tonnes from 4.2 million the previous year.
While the cyclone poses a threat to sugar, beleaguered cattle farmers may welcome widespread rain. Until now, drought has been forcing farmers to slaughter record numbers of animals as grazing land wilted.
The Great Barrier Reef, one of Australia's most popular tourist attractions, stretches more than 2,000 km along the Queensland coast and is the world's largest coral reef system.
The reef has lost half its coral cover in the last 27 years, with storms responsible for nearly half of that damage, the Australian government said in a 2012 report.Last Mod: 11 Nisan 2014, 15:34


text:
Women's leather biker jacket
Scuderia Ferrari Store Exclusive
This biker jacket, made of soft lamb nappa leather, features contrasting color details.
The shoulders, the collar and the upper part of the sleeves are red, while on the chest and on the arms a white stripe gives the jacket dynamism. The silhouette is slim fit, the collar closes with snaps and the bottom is in rib knit. Get set for a new wardrobe essential with this leather jacket enhanced by details including a two way zipper, tone on tone Ferrari emblem on the left sleeve and front welt pockets with concealed closure. Entirely Made in Italy, this women's jacket combines contemporary flair with timeless style.
- Zipper on the back of the sleeves
- Front welt pockets with concealed fastening
- Ferrari Shield
- Composition: 100% Soft Leather
We offer both Standard and Express shipping: choose the service that best meets your needs at checkout.
We provide an easy return service: just ship your items back to us with a shipping service of your choice within 30 days of delivery.


text:
Authorities across Los Angeles County arrested 1,982 people suspected of driving under the influence of drugs or alcohol, a slight decrease over the three-day holiday weekend last year.
In 2013, 2,313 drivers were arrested from the reporting period of 12:01 a.m. Friday to midnight Monday, according to the Avoid the 100 Los Angeles County DUI campaign.
Of the arrests this year, 74 occurred after an injury crash had occurred, according to Wendy Brewer, a community service officer for county program.
Locally, Long Beach police arrested one driver for suspected DUI during a checkpoint from 7 p.m. Saturday to 3 a.m. Sunday on Ocean Boulevard and Pacific Avenue, police said Tuesday.
During the eight-hour operation, which was aided by Long Beach Police Explorers and Long Beach Search & Rescue, 1,633 vehicles passed through the checkpoint with 544 drivers being screened.
One driver was also arrested for a misdemeanor warrant; three were cited for unlicensed driving; two drivers were cited for suspended license; and four drivers were cited for unsafe driving.
In Bellflower, two motorists suspected of driving under the influence of marijuana were arrested during a sobriety checkpoint ahead of the Labor Day weekend, while 11 others were taken into custody for alleged license violations.
Sheriff's deputies began the operation at 6 p.m. Thursday and continued through 1 a.m. on Friday on Artesia Boulevard, just east of Lakewood Boulevard, said Sgt. Britta Steinbrenner of the Los Angeles County Sheriff's Department.
Of the 1,637 vehicles that passed through the checkpoint, 1,541 of them were stopped and checked, Steinbrenner said.
In addition to the two alleged marijuana DUI arrests, one more person was booked for illegal narcotics possession, Steinbrenner said.
In addition, four people with suspended or revoked licenses were arrested, while seven unlicensed drivers were taken into custody, according to the sergeant.


text:
Our exhibitions access crucial developments in the field of contemporary art, and are now conceived to involve presenters and viewers more, and to be as affordable as possible. We promote more collaboration with host institutions, encourage them to modify exhibitions, and work with a range of contemporary art curators to create new flexible projects.
The Curator's Perspective is an itinerant public discussion series taking place in a variety of venues throughout New York, featuring an international curator who distills current happenings in contemporary art, including the artists they are excited by, exhibitions that have made them think, and their views on recent developments in the art world.
ICI organizes public programs in New York, across the U.S, and around the world that provide a platform for curators to share their research and experiences with the public. Through partnerships with a range of institutions, ICI enables new audiences and curators alike to understand and navigate the rapidly growing field of curating, while also increasing access to current developments in contemporary art internationally.
Through ICI on the Move, ICI is expanding its public programming reach nationally, working with venues that host our traveling exhibitions, developing visiting curator tours, and organizing public discussions at art fairs to bring emerging and established practitioners together to exchange ideas and share their experiences.
ICI's annual New York Studio Events series not only grants you intimate access to your favorite artists year round, but also helps ICI respond to the rapidly developing art world of today, ensuring that we connect you with momentous practitioners at the exact time they are presenting significant works.
The Curatorial Intensive is ICI's short-term, low-cost training program that offers emerging curators the chance to develop their exhibition ideas and make connections to leaders in the field, providing the opportunity to forge new international networks through peer-group education.
The Curator's Network is a new professional membership group developed to bring together curators who want to share their work and exchange information with other professionals in the field through a wide range of online resources. The fully tax-deductible annual subscription is $100.
DISPATCH is ICI's quarterly online journal that features different curators points of view on current developments in art. Practitioners based in different cities around the world are invited to use DISPATCH as their virtual base, building their research over time through text, image, and video.
Independent Visions has been inaugurated to reflect ICI's commitment to supporting international curators early in their careers who have shown exceptional creativity and prescience in their exhibition-making, research, and related writing.
Members of The Curator's Network gain access to the information we think curators should know about, including an online guide to all things curating and a directory of ICI's network to connect with other colleagues from around the world.
In addition to gaining insider access to contemporary art, ICI supporters directly contribute to the production of our traveling exhibitions and training opportunities. In the past, supporter involvement has allowed artists and curators to explore new ideas and to present compelling contemporary art to diverse audiences. Today, joining ICI means helping us stay dynamic for the next 35 years!
The Artist Video Profiles are a set of fourteen short films depicting contemporary artists discussing their creative methods and techniques in their private work settings. Created in partnership with Talking Point Films, LLC, the Artist Video Profiles were filmed in artists' studios during the Fall of 2007 and the Spring of 2008.
A comprehensive list of the curators ICI has worked with to produce innovative traveling exhibitions since 1975.
A partial list of the artists whose work ICI has exhibited since 1975.
In 35 years of operation ICI has organized 116 traveling exhibitions, profiling the work of more than 3,700 artists. The shows have been presented in 590 museums, university art galleries, and art centers in 48 states and 25 countries worldwide.
The following institutions have presented one or more ICI exhibitions.
Welcome to the Press Room, where you can view and download press kits, releases, and images for current and upcoming ICI exhibitions, as well as read recent press coverage of ICI programs.
Independent Curators International (ICI)
Michelle Jubin
Communications Administrator
P 212.254.8200 x21
Independent Curators International (ICI)
799 Broadway, #205
New York, NY 10003
Since 1990, ICI has commissioned artists to produce limited edition works to raise funds for its innovative programs and publications. Currently available limited editions include works by John Baldessari, Joseph Kosuth, Dana Schutz, Laurie Simmons and Alec Soth.
ICI is dedicated to producing high-quality and affordable publications to accompany its traveling exhibitions. Visit our store to browse ICI's roster of over 70 publications.


text:
Fantasy-inspired Color Combinations Invigorate the Fall Palette
CARLSTADT, N.J., Feb. 11, 2010 – Pantone LLC, an X-Rite company (NASDAQ: XRIT), and the global authority on color and provider of professional color standards for the design industries, today announced the PANTONE® Fashion Color Report Fall 2010. The report features the top 10 colors for women's fashion for fall 2010, along with designer sketches, quotes and headshots, and is available for free download on the Pantone Web site at www.pantone.com/fall2010. The release of the PANTONE Fashion Color Report coincides with the beginning of New York Fashion Week.
The top colors for women's fashion for fall 2010 are:
PANTONE 13-0632 Endive
PANTONE 15-1050 Golden Glow
PANTONE 16-1546 Living Coral
PANTONE 19-1764 Lipstick Red
PANTONE 18-3027 Purple Orchid
PANTONE 19-1526 Chocolate Truffle
PANTONE 16-5418 Lagoon
PANTONE 18-0538 Woodbine
PANTONE 14-1107 Oyster Gray
PANTONE 14-1307 Rose Dust
"Mindful of consumers' need for practicality, plus their desire for newness, designers offer many options for women to extend and embellish their wardrobes this fall," said Leatrice Eiseman, executive director of the Pantone Color Institute®. "Building on the color palette from spring, this season's offerings include innovative takes on fundamental basics, as well as transporting, lively colors that conjure images of travel and adventure, whether real or aspirational."
In addition to designer contributions, the report features commentary from fashion insiders and leading retailers regarding current fashion trends and new color rules for 2010. Industry gurus highlighted in the report include: India Hicks, creative partner at Crabtree & Evelyn; Cate Adair, costume designer for "Desperate Housewives"; Collier Strong, celebrity make-up artist; Eric Sauma, owner of Mood Fabrics (featured on "Project Runway"); and Constance White, style director at eBay. Contributors from Neiman Marcus, Saks Fifth Avenue and Macy's also offer their insights.
Fashion designers continue to exhibit a degree of caution for fall 2010, yet offer a palette of beauty and excitement with a blending of colors, some with similar undertones, in surprising and intriguing combinations. Inspired by the ongoing phenomenon of film animation, vivid colors are often juxtaposed in inventive ways, creating arresting and extraordinary color combinations.
Exotic Purple Orchid, a purple leaning to fuchsia, is an unexpected choice for fall, imbuing a bit of magic and vibrancy to the season. Elegant Chocolate Truffle, evocative of delicious treats, is a rich brown with piquant plum undertones, that pairs tastefully with Purple Orchid. Not your mother's avocado green, Woodbine takes last season's neutral greens to a whole new level, and when mixed with Purple Orchid and Chocolate Truffle, results in a stunning combination.
Lagoon, this season's turquoise – Pantone's 2010 color of the year – is guaranteed to add a tropical splash. A great color for fall and winter escapes, Lagoon is a popular hue, especially in accessories, pairing dynamically with all shades of red. Lipstick Red, a deeper, more dramatic sensual red, makes its imprint on fall, particularly in cosmetics.
Reminiscent of a radiant sunset on a brisk autumn evening, Golden Glow, an earthy, deepened shade of yellow, creates a retro look with Purple Orchid or Woodbine. A softer, more inviting orange with a hint of pink undertone, Living Coral is the perfect complement to Lagoon, whether heading for a tropical destination or just fantasizing about it. Crisp Endive, a revitalizing yellow-green, adds freshness to this season's top ten, and will enliven any wardrobe. Add it to Lagoon, Chocolate Truffle and Purple Orchid for an invigorating fall look.
Oyster Gray, a classic neutral that grounds the palette, is a lighter take on the traditional fall gray, as designers heed consumers' concern about the economy and deliver investment pieces that carry through to spring 2011. Rose Dust, a flattering beige, offers an ethereal, romantic, wispy option to span the seasons.
The colors featured in the PANTONE Fashion Color Report are culled from the PANTONE FASHION + HOME Color System, the most widely used and recognized color standards system in the world. Each season, Pantone surveys the designers of New York Fashion Week to collect feedback on prominent collection colors, color inspiration and color philosophy. This information is used to create the PANTONE Fashion Color Report, which serves as a reference tool throughout the year for fashion enthusiasts, reporters and retailers.
About Pantone
Pantone LLC, a wholly owned subsidiary of X-Rite, Incorporated, has been the world's color authority for 45 years, providing design professionals with products and services for the colorful exploration and expression of creativity. Always a source for color inspiration, Pantone also offers designer-inspired products and services for consumers. More information is available at www.pantone.com.
About X-Rite
X-Rite, Incorporated, is the global leader in color science and technology. The company, which now includes color industry leader Pantone, develops, manufactures, markets and supports innovative color solutions through measurement systems, software, color standards and services. X-Rite's expertise in inspiring, selecting, measuring, formulating, communicating and matching color helps users get color right the first time and every time, which translates to better quality and reduced costs. X-Rite serves a range of industries, including printing, packaging, photography, graphic design, video, automotive, paints, plastics, textiles, dental and medical. For further information, please visit www.xrite.com.


text:
Curtis Taking Shots At Weezy: 50 Cent Says Lil Wayne Grew Up On TV, His Lyrics Can't Be Factual At Howard University!
50 cent mentions lil wayne at his howard university:
Please click the "Report" button below if the video on this page is not working properly.
Comments will only be displayed by verified emails. No Spamming or Racism.


text:
Product Highlights
This item is noncancelable and nonreturnable.
The Formatt 4 x 4" 81C Color Conversion Filter controls the bluish coloration that affects daylight film. They can also remove excessive blue from the effects of electronic flash.
It's Autumn. The clouds are low hanging and the sky is "patchy blue". You've gone for a ride upstate to the mountains and the light in open shade is bluish. A photo taken of your girlfriend with daylight balanced film leaning against the side of a barn will yield bluish tones that she might not find particularly flattering. An 81C filter will replace even more yellow than an 81B and place her skin tones on a more "warmish" level.
An 81C can also be used with electronic flash to reduce the amount of "blue" generated by the flash. The 81 series (81A, B, C, D and EF) allows you to choose how much warmth you wish to replace in the image.
This filter can be used by the pro and amateur alike, weekend photo warrior or pro cinematographer and must be considered an essential addition to any photo arsenal.
Note: Whereas the 81 Series of filters creates a feeling of warmth, the 82 Series creates a feeling of coolness.
|Color Conversion
|4 x 4" (100 x 100mm, 4mm thick)
|Filter Factor
|+1/3 stop
|Not Applicable
|Not Applicable
|The 81 series adds warmth to the image
|Good for general scenics when the photographer wishes to remove the bluish cast from open shade or just add warmth to the photograph, with an 81EF having the greatest effect
|Color Temperature
|Decreases color temperature from 3600 - 3200 Kelvin
|Schott-Desag B270 Crown Optical Glass
|Front Filter Thread Size
|Not Applicable
|Front Lens Cap Size
|Not Applicable
|Packaging Infofrasuuztvqfzwwyzvudt
|Package Weight
|0.4 lb
|Box Dimensions (LxWxH)
|2.0 x 2.0 x 2.0"


text:
Scouting for Boys
From MeritBadgeDotOrg
|Scouting for Boys
| This is a stub... Please help improve this article or section by expanding it.
Further information might be found on the talk page.
Scouting for Boys: A Handbook for Instruction in Good Citizenship was the first book on the Scouting Movement. Written and illustrated by Robert Baden-Powell, it is based on his boyhood experiences, his experience with the Mafeking Cadet Corps during the Second Boer War, and on his experimental camp on Brownsea Island, England. It went on to become the fourth bestselling book of the 20th century.


text:
Debugging C/C++ Projects Tutorial
March 2013 [Revision number: V8.0-1]
The following short tutorial takes you through some of the features for debugging a C or C++ project in NetBeans IDE.
To follow this tutorial, you need the following software and resources.
See the NetBeans IDE Installation Instructions and Configuring the NetBeans IDE for C/C++/Fortran for information on downloading and installing the required software.
Creating the Sample Project
The NetBeans IDE with C/C++ uses the gdb debugger and provides numerous features for debugging your projects. To explore these features, you will use the Quote project. If you have not already created this project, do the following:
Creating Breakpoints
You can create and manipulate breakpoints in your code at any time without starting a debugging session.
Creating and Removing a Line Breakpoint
Creating a Function Breakpoint
Starting a Debugging Session
When you start a debugging session, the IDE starts the gdb debugger, then runs the application inside the debugger. The IDE automatically opens the debugger windows and debugger toolbar and prints debugger output to the Output window.
Inspecting the State of the Application
See Also
Please see the C/C++ Learning Trail for more articles about developing with C/C++/Fortran in NetBeans IDE.


text:
Moderators: Three Stars, dagny, pfim, netwolf
canaan wrote:Kind of surprised that the oil aren't interested
Tom Dougherty @todougherty 4h
Anything more than Matt Read and a 2nd round pick is too much for Jonathan Bernier. It's the Flyers, so expect Giroux, Voracek and a 1st.
Rylan wrote:Bernier could be a starter for half the league.
Users browsing this forum: Daniel and 3 guests


text:
The Grammy-nominated Tom Harrell Quintet will perform at Hope College on Monday, Dec. 3, at 7:30 p.m. in Dimnent Memorial Chapel.
Harrell has been praised by "Newsweek" for his pure melodic genius, and he is a frequent winner in "Down Beat" and "Jazz Times" magazines' Critics and Readers Polls. He is also a Trumpeter of the Year nominee two years in a row, for the 2010 and 2011 Jazz Journalists Association Awards. His discography spans more than 260 recordings and his career more than four decades.
Harrell has four successful recordings with the current members of his quintet, which includes tenor saxophonist Wayne Escoffery, pianist Danny Grissett, drummer Johnathan Blake and his bassist of 12 years, Ugonna Okegwo. "The Time of the Sun" (2012) is the group's most recent release. The quintet's previous albums, "Roman Nights" (2010), "Light On" (2007) and "Prana Dance" (2009), were released to wide critical acclaim and won SESAC awards for topping the radio charts in the U.S.
A graduate of Stanford University with a degree in music composition, Harrell is a prolific composer and arranger. Carlos Santana, Cold Blood, Azteca, Vince Guaraldi, Hank Jones, Kenny Barron, the Vanguard Jazz Orchestra, Danish Radio Big Band, WDR Big Band, Brussels Jazz Orchestra, Metropole Orchestra and Arturo O'Farrill & the Afro-Latin Jazz Orchestra are among the many who have recorded or performed his work. Harrell's composition and arrangement, "Humility," was recorded for the latter's 2008 release, which won a Grammy for the Best Latin Jazz Album.
In addition to the 26 albums and thousands of concerts worldwide as a leader, Harrell has worked with important figures in jazz history including Stan Kenton, Woody Herman, Dizzie Gillespie, Horace Silver, Bill Evans, Gerry Mulligan, Art Farmer, Phil Woods, Lee Konitz, Sam Jones (with whom he briefly co-led a big band in the 1970s), Jim Hall and Charlie Haden, and with contemporaries such as Joe Lovano and Charles McPherson. In 2006, Harrell was awarded a Chamber Music America grant with which he composed and performed new pieces for trumpet and piano. He also wrote symphony orchestra arrangements for the French Orchestre National de Lorraine and the vocalist Elisabeth Kontomanou for a live recording album released in 2009, "Siren Song."
Tickets for the Monday, Dec. 3, concert are $10 for regular admission, $7 for senior citizens, and $5 for children 18 and under, and are available at the ticket office in the main lobby of the DeVos Fieldhouse. The ticket office is open weekdays from 10 a.m. to 5 p.m. and can be called at (616) 395-7890. Tickets are also available online at tickets.hope.edu/ticketing/
The DeVos Fieldhouse is located at 222 Fairbanks Ave., between Ninth and 11th streets. Dimnent Memorial Chapel is located at 277 College Ave., on College Avenue at 12th Street.


text:
FOX Business: The Power to Prosper
Continue Reading Below
After taking a thrashing in the last session, the markets slid solidly into the red Thursday in a fairly broad-based retreat. All but one major sector slumped.
Today's Markets
As of 3:15 p.m. ET, the Dow Jones Industrial Average fell 55.4 points, or 0.43%, to 12878, the S&P 500 dipped 9.3 points, or 0.69%, to 1385 and the Nasdaq Composite slumped 29.3 points, or 1%, to 2907.
The S&P 500, considered one of the best barometers of U.S. equities, tumbled 2.4% on Wednesday in its worst day on a percent basis since June. The broad-market index is down less than 2% for the month, but is still up nearly 11% for the year.
On Thursday, every sector besides utilities was in the red. Among the worst performers were consumer discretionary, material and energy players.
The focus on Washington, D.C. that has consumed trading desks in the past couple sessions eased somewhat Thursday, with data and European news coming back into the spotlight.
On the economic docket, a report from the Commerce Department unexpectedly showed the U.S. trade deficit hitting its narrowest level since December 2010 in September. The deficit fell to $41.6 billion for the month from $43.8 billion in August. Economists expected a reading of $45 billion. While the gauge that measures the difference between exports and imports is a lagging indicator, it does figure directly into broader measures of economic output.
Another report from the Labor Department showed new claims for unemployment benefits falling to 355,000 last week from 363,000 the week prior. Claims were expected to rise to 370,000. A Labor Department analyst says superstorm Sandy depressed claims in at least one state and resulted in an increase in claims in others, according to a report by Reuters. The stubbornly-slow recovery for the labor market has been a major focus among economists in recent months.
On the European front, Greece's parliament approved a fresh round of austerity measures by a margin of 153 to 147. The move is important because it likely clears the way for the country to receive more rescue aid from the European Union and International Monetary Fund, which will allow it to stave off a debt default.
The Bank of England held its benchmark interest rate at 0.5% and the size of its quantitative easing program at 375 billion pounds, as expected. The European Central Bank left its main refinancing rate at 0.75% as expected. ECB President Mario Draghi is set to hold a news conference later in the day.
In corporate news, Apple (NASDAQ:AAPL) shares came under heavy selling pressure after plunging into bear market territory on Wednesday. The company's giant market capitalization means movements in its shares have an outsize impact on the broader markets.
J.P. Morgan Chase (NYSE:JPM) said in a regulatory filing that it has reached an "agreement in principle" with the Securities and Exchange Commission on a probe related to mortgage backed securitizations by two of its units. The biggest U.S. bank by assets also said the Federal Reserve approved a $3 billion share buyback program for the first quarter of 2013.
In commodities, oil prices bounced back after sustaining the worst selloff in close to a year. The benchmark contract traded in New York rose 65 cents, or 0.77%, to $85.09 a barrel. Wholesale New York Harbor gasoline climbed 0.71% to $2.607 a gallon.
In metals, gold gained $12.00, or 0.7%, to $1,726 a troy once.
Foreign Markets
The Euro Stoxx 50 gained 0.88% to 2501, the English FTSE 100 rose 0.33% to 5811 and the German DAX advanced 0.51% to 7269.
In Asia, the Japanese Nikkei 225 sold off 1.5% to 8837 and the Chinese Hang Seng plunged 2.4% to 21567.


text:
Friday, May 14, 2010
Posted by Gillian Riley Lepisto & Heather Grace Gordy of phrizbie-design.com at 5:43 AM 1 comments Links to this post
Subscribe to: Posts (Atom)
Welcome to our glamour inspiration blog. Gorgeous graphic design and exquisite website design are fed from a love of not just art, but fashion, music, science, dance, nature, architecture and interior design. Enjoy this luscious little bit of tasty eye candy. If you have something you would like us to share just send us an email xoxo